CUE Kerri-Ann Millar buys $8K worth of shares
Jan 08, 2026, 11:36 AM
-2.47%
What does CUE do
Cue Biopharma, a Boston-based clinical-stage biopharmaceutical company, develops biologic drugs for immune system modulation to treat cancers and autoimmune disorders. Its key candidates include CUE-101 for HPV-positive HNSCC and CUE-102 for Wilms' Tumor 1 protein.
Kerri-Ann Millar bought 1,000 shares of CUE on 29 August at $8.48 per share, worth a total of $8K. They now own 1,000 CUE shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.